Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
14 13 Search
2025
The MAO‐B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti‐Androgen and Cytostatic Agents
Pharmacology Research & Perspectives
2025
PEA3 Transcription Factors, Role in Invasion, Proliferation and Radioresistance of Glioblastoma Stem Cells
Journal of Cellular and Molecular Medicine
2025
Role of Androgen Receptor in Melanoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic Implications
Cancers
2024
Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis
Biomedicines
2023
mRNA Levels of Aromatase, 5α-Reductase Isozymes, and Prostate Cancer-Related Genes in Plucked Hair from Young Men with Androgenic Alopecia
International Journal of Molecular Sciences
2023
Identifying key transcription factors and immune infiltration in non-small-cell lung cancer using weighted correlation network and Cox regression analyses
Frontiers in Oncology
2023
The Transmembrane Protein TM4SF3 Interacts With AR and AR-V7 and is Recruited to AR Target Genes
Endocrinology
2022
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective
Oncology Research
2022
Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer
Endocrinology
2022
MicroRNA-149 suppresses osteogenic differentiation of mesenchymal stem cells via inhibition of AKT1-dependent Twist1 phosphorylation
Cell Death Discovery
2022
HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET
Journal of Experimental & Clinical Cancer Research
2021
Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR
Oncogene
2021
Capicua in Human Cancer
Trends in Cancer
2021
MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1–cMET signaling
Oncogene